Cell Therapeutics, Inc. (CTIC) Has four (FDA) clinical trial updates December 31st 2012!
Sent Friday, November 30, 2012
View as html
Insiders bought over 300,000 shares today!
Cell Therapeutics, Inc. (CTIC) -Nasdaq
Four (FDA) updates December 31st! All on this day! Stock is a buy!!!
Phase 3 Pacnitinib
Phase 3 Tosedostat
Phase 2 Pixantrone
Phase 3 Opaxio
Insiders bought 300,000 shares this morning!
Short term price target is $3.25
Cell Therapeutics, Inc.
501 Elliott Avenue West
Seattle, WA 98119
United States - Map [
Website: http://www.celltherapeutics.com [
Cell Therapeutics, Inc. engages in the development, acquisition,
and commercialization of drugs for the treatment of cancer. It is
developing Pixuvri, a novel anthracycline derivative for the
treatment of hematologic malignancies and solid tumors; OPAXIO, a
chemotherapeutic agent that links paclitaxel to a biodegradable
polyglutamate for treating ovarian, brain, esophageal, head, and
neck cancers; Brostallicin, a synthetic DNA minor groove binding
agent; and Bisplatinates, a platinum-based chemotherapy drug to
treat various cancers. The company, in collaboration with Chroma
Therapeutics, Ltd., is also engaged in developing Tosedostat, an
oral aminopeptidase inhibitor. Cell Therapeutics, Inc. was founded
in 1991 and is headquartered in Seattle, Washington.
Stock recommendations and comments presented on
HotPennyStocksOnline.com are solely those of the analysts and
experts quoted. They do not represent the opinions of
HotPennyStocksOnline.com on whether to buy, sell or hold shares of
a particular stock.
Investors should be cautious about any and all stock
recommendations and should consider the source of any advice on
stock selection. Various factors, including personal or corporate
ownership, may influence or factor into an expert stock analysis or
All investors are advised to conduct their own independent research
into individual stocks before making a purchase decision. In
addition, investors are advised that past stock performance is no
guarantee of future price appreciation [
Always do your best. What you plant now, you will harvest later.
Og Mandino [
Kevin P. Ryan: President
Sumant Chittiprolu: Vice President
Matthew Fisher: CEO
Anthony Lero: Director of Marketing and Sales
http://hotpennystocksonline.com [ http://hotpennystocksonline.com/ ]